BUCCOLAM (midazolam): Risk of inhalation/ingestion of tip cap of prefilled plastic syringes

Dear Healthcare Professional,

Further to the previous communication dated 22nd November 2017, Shire Services BVBA, in agreement with the European Medicines Agency and Medicines and Healthcare products Regulatory Agency (MHRA), would like to inform you of the following:

Summary

- The translucent tip-cap of BUCCOLAM prefilled syringes can on occasion remain attached to the syringe tip when pulling off the red cap with the risk of being detached into the patient’s mouth and inhaled or ingested upon administration.
- If the translucent tip-cap remains on the syringe, it needs to be removed manually before giving the medicine.
- Please inform parents and caregivers about this risk and the need to perform the appropriate check before administering the product (see instructions below).
- Pharmacists are encouraged to proactively communicate the information included in the instructions attached to this letter to patients, parents and caregivers who have been dispensed BUCCOLAM and who have not already been made aware. Further supplies of BUCCOLAM will contain these instructions, to be given to patients with their pack.

Background on the safety concern
Shire has received reports that, when removing the red cap from the syringe, the translucent tip-cap has remained on the syringe tip. This has resulted in incidents (2) of the translucent tip-cap becoming detached into the patient’s mouth during administration and being accidentally aspirated or ingested.

Instructions for safe administration
Before administering BUCCOLAM, patients, parents and caregivers should check that the translucent tip cap is attached to the removed red security cap, as shown in Figure 1 below. The translucent cap should not remain attached to the syringe, as shown in Figure 2 below. If the tip cap remains attached to the syringe, it should be removed manually before administration to prevent the translucent tip cap from accidentally entering the patient’s mouth.
Shire is working with the Regulatory Authorities to resolve this issue.

In the meantime, please inform patients, caregivers, and other healthcare providers who will be or have been dispensed BUCCOLAM about this risk and the instructions required to minimize it, if they have not already been made aware.

To support your communication, Shire has provided the below annex to support safe administration of BUCCOLAM. Please provide this annex to patients, parents, and caregivers.

**Further information**

BUCCOLAM is approved in the European Economic Area for the following therapeutic indication:

- Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children, and adolescents (from 3 months to < 18 years).

BUCCOLAM must only be used by parents/caregivers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

Detailed information on this product is available on the website of the European Medicines Agency: [http://www.ema.europa.eu](http://www.ema.europa.eu)

**Call for reporting**

Please report any suspected adverse reactions to any medicine to the Medicines and Healthcare products Regulatory Agency through the Yellow Card Scheme. Please report:

- All suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling, or incapacitating, those that cause a congenital abnormality, or result in hospitalisation, and those that are considered medically significant for any other reason.
- All suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

It is easiest and quickest to report ADRs online via the Yellow Cards website - [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk)
Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gov.uk
- at the back of the BNF, MIMS, ABPI Compendium or ordered by calling the Yellow Card Information Service freephone on 0800 731 6789
- or by downloading and printing a form the Yellow Card section of the MHRA website.

Any suspected adverse reactions observed during use of BUCCOLAM 2.5 mg, 5 mg, 7.5 mg and 10 mg oromucosal solution may also be reported to Shire at +44 (0)1256 894000 or emailed to: drugsafety@shire.com

Company contact point

Should you have any questions or require additional information on the use of BUCCOLAM 2.5 mg, 5 mg, 7.5 mg and 10 mg oromucosal solution, please contact Medical Information at Tel: 0800 055 6614 or by email at MedinfoEMEA@shire.com

Sincerely,

Dr Daniel (Toby) Shephard BSc. MBBS MFPM
Country Medical Head UK & Ireland
Shire

Felicia Pinto
UK & Ireland Head Regulatory Affairs
Shire
Buccolam Prefilled Plastic Syringes: instructions for correct administration

The clear tip-cap of Buccolam syringes can sometimes remain attached to the syringe after the red cap has been taken off. If this happens, the tip-cap can detach in the patient’s mouth and they might breathe it in or swallow it. If this happens, this could be a choking hazard.

Continue to give Buccolam as your doctor, nurse or pharmacist has told you to.

Buccolam remains safe to use. Before use of Buccolam, you must follow the instructions below:

Correct

1. Before giving Buccolam, pull the red cap off the end. Check the clear tip-cap is attached to the red cap, as shown.

Incorrect

2. The clear tip-cap should not be attached to the syringe, as shown.

3. If the clear tip-cap is still attached to the syringe, you should pull it off before giving Buccolam to prevent it from going into the patient’s mouth.

If you think the tip-cap is in the patient’s mouth, do not insert a finger into the mouth to look for it or remove it. Instead, turn the patient onto their side (recovery position) and make sure they spit it out when they stop fitting.

Call for reporting

If you get any side effects, talk to your doctor, pharmacist or nurse. You should also tell them about any occasions in which the translucent tip-cap remained attached to the syringe.

You can also report side effects directly via the Yellow Card Scheme website https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects, you can help provide more information on the safety of this medicine.